Bio-Techne Corporation (TECH) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Bio-Techne Corporation (TECH) Profile & Business Summary
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Key Information
| Ticker | TECH |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://www.bio-techne.com |
Market Trend Overview for TECH
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-07-13 (ET)
As of 2026-07-13, TECH is moving sideways without a clear direction. Over the longer term, the trend remains bullish.
TECH last closed at 71.36. The price is about 0.4 ATR above its recent average price (70.36), and the market is currently in a sideways market without a clear direction. Price at 71.36 is moving between minor support near 68.93 and minor resistance near 73.79. Direction remains unclear. View Support & Resistance from Options
The market is moving sideways, with no clear direction. Both upside and downside risks remain in play.
Trend score: 35 out of 100. Overall alignment is unclear. The market is currently in a sideways market without a clear direction. The longer-term trend is still positive, but short-term signals are not yet confirming it.
A key downside risk boundary is near 62.12. If price falls below this area, the current structure would likely weaken further.
A systematic trend-activation signal was most recently triggered on 2026-06-04, reflecting a technical shift toward positive directional alignment.
[2026-06-22] Price moved quickly and looked strong, but participation was limited.
Recent price action shows orderly upward progression with no major deterioration in bar-level efficiency. Structural conditions remain broadly constructive.
There was no clear sign of meaningful positions being carried into the overnight session.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not issue an actionable directional forecast. Predictability is 39%, agreement is 70%, and reversal risk is 18%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is modestly above the recent estimated cost basis of 69.76, so the recent structure is still on the firmer side. Price is above the main cost band (70.66 to 70.89), and about 98% of recent positioning is already in profit. That supports trend strength, but it also raises the chance of profit-taking if momentum cools. The lower down support area sits around 70.43 to 71.20, and it still looks fairly solid. Recent trading is fairly concentrated, so the nearby heavy zones may matter more than usual. The main cost band is fairly wide relative to recent ATR, so this structure may behave less cleanly than a tighter setup. From a trading point of view, the trend still has support, but because the main support sits lower down around 70.43 to 71.20, the key is whether pullbacks remain controlled before dropping back into that zone.